BIOPOR Bioporto A/S

BioPorto A/S - Annual General Meeting

BioPorto A/S - Annual General Meeting

April 14, 2020

Announcement no. 9

BioPorto A/S - Annual General Meeting

Today, BioPorto A/S held its Annual General Meeting during which the report on the Company’s activities was reviewed and the 2019 Annual Report was adopted. The proposed profit/loss allocation was also adopted and discharge of liability was granted to the Board of Directors and the Executive Management. Finally, the remuneration for the Board of Directors was approved.

Thomas Magnussen, Torben A. Nielsen, Kirsten Aarup Drejer, Christopher Lindop and Michael S. Singer were re-elected as members of the Board of Directors. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its Chairman and Torben A. Nielsen as its Vice Chairman. 

The proposals from the Board of Directors under item 6 of the agenda were all adopted, and included: a) Amending the Articles of Association regarding shareholders’ notification of attendance for a general meeting, b) Amending the standard agenda for the Annual General Meeting in Article 8 in the Articles of Association, c) Renewing the authorization to issue warrants for up to DKK 2,500,000 following decision by the Board of Directors to amend its original proposal of up to DKK 6,600,000 shares, d) Approving the Company’s revised Remuneration Policy and e) Authorization to the Chairman of the general meeting.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

Hellerup, April 14, 2020

BioPorto A/S

The Board of Directors

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
14/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift me...

BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift med fuld eksekvering af strategiske mål og stærk NGAL-salgsvækst 15. august 2025Meddelelse nr. 19 BioPortos delårsresultat for andet kvartal 2025 - Fortsat fremdrift med fuld eksekvering af strategiske mål og stærk NGAL-salgsvækst. København, Danmark, 15. august 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) offentliggjorde i dag delårsregnskab for andet kvartal 2025 og en forretningsopdatering. Fortsat fremdrift på vigtige strategiske milepæle i 2. kvartal 2025 Fuld realisering af de ...

 PRESS RELEASE

BioPorto Interim Result for the Second Quarter of 2025 - Continued pro...

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. August 15, 2025Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen, Denmark, August 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the second quarter of 2025 and a business update. Continued progress on key strategic milestones f...

 PRESS RELEASE

BioPorto attends the Association for Diagnostics & Laboratory Medicine...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. July 28, 2025News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. BioPorto is pleased to announce its attendance and the general multiple NGAL and Acute Kidney Injury (AKI) focused elements of the Association for Diagnostics Medicine meeting, this year held in...

 PRESS RELEASE

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

 PRESS RELEASE

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch